---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-26-000037"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:33:31.329907+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes

## Summary
- Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.
- Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.
- Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.
- KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.
- All other directors elected with over 90% support from votes cast (excluding broker non-votes).

## SEC filing metadata
- accession: 0000879407-26-000037
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/0000879407-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/arwr-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-26-000037
- JSON: https://secwatch.observer/filing/0000879407-26-000037.json
- Plain text: https://secwatch.observer/filing/0000879407-26-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.